Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody’s target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi.

The post Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck appeared first on MedCity News.

Leave a Replay

Sign up for our Newsletter

Contact Us